Implications for prenatal genetic testing after reversal of Roe v. Wade in the United States

Abstract

Prenatal genetic screening and diagnostic testing should be offered in every pregnancy as a standard of care in the United States. This testing is important for patients who choose to continue their pregnancies, but it is also common for patients to choose termination after a positive result. Options for diagnostic testing vary by gestational age, with chorionic villus sampling (CVS) offered at an earlier gestational age (10-13 weeks) than amniocentesis (15 weeks gestation). Our objective was to determine the effect of new gestational age-based abortion restrictions on options for feasible genetic diagnostic testing by state.